Shilpa Gupta, MD, Cleveland Clinic

Articles

Dr. Gupta on Challenges of Identifying Biomarkers in Bladder Cancer

October 15th 2019

Shilpa Gupta, MD, discusses the challenges of identifying predictive biomarkers in bladder cancer.

Dr. Gupta on Enzalutamide/Chemo Combo in Metastatic Bladder Cancer

September 10th 2019

Shilpa Gupta, MD, associate professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the results of the phase I/Ib trial investigating the use of frontline enzalutamide, gemcitabine and cisplatin in metastatic bladder cancer.

Dr. Gupta Discusses Combination Immunotherapy in RCC

September 10th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses combination immunotherapy in renal cell carcinoma.

Dr. Gupta on Genomic Characterization of MIBC Histology to Predict Response

August 9th 2018

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses genomic characterization of muscle invasive bladder cancer histology to predict therapy response.

Dr. Gupta on Impact of Pembrolizumab Plus Bevacizumab Findings in RCC

July 10th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the impact of the phase Ib/II results of pembrolizumab (Keytruda) plus bevacizumab (Avastin) in patients with metastatic renal cell carcinoma.

Dr. Gupta on Phase Ib/II Trial of Pembrolizumab With Bevacizumab in RCC

June 14th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the phase Ib/II studies of pembrolizumab with bevacizumab for the treatment of patients with metastatic renal cell carcinoma.

Dr. Gupta on Evolving Treatments for RCC

September 7th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses the CABOSUN trial investigating cabozantinib (Cabometyx) and sunitinib (Sutent) in patients with renal cell carcinoma (RCC).

Dr. Gupta on PD-L1 as a Biomarker in Kidney Cancer

August 23rd 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses PD-L1 as a biomarker in kidney cancer.

Dr. Gupta Discusses the Shifting Landscape of Kidney Cancer

August 11th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses the shifting landscape of kidney cancer.

Dr. Gupta Discusses Adjuvant Immunotherapy in Kidney Cancer

August 8th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses adjuvant immunotherapy in kidney cancer.

Dr. Gupta on VEGF Inhibitors Combined with Immunotherapy in Kidney Cancer

May 17th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses combining VEGF inhibitors with immunotherapy for patients with kidney cancer.